# Clinical Trials Data EGFR - Document 12

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the information provided in the clinical trial eligibility criteria, there is no mention of EGFR gene mutation status as a determining factor for eligibility. The key criteria for eligibility appear to be:  
  
1. A diagnosis of refractory non-small cell lung cancer.  
2. Having received sorafenib tosylate on protocol ECOG-E2501.  
3. Availability of blood specimens.  
  
Given these criteria, a patient with an EGFR gene mutation could be eligible for the clinical trial as long as they meet the specified disease characteristics and have met the prior therapy conditions. The presence of an EGFR mutation in itself does not appear to be a disqualifying factor based on the given information.